Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEERS: Pembrolizumab + Lenvatinib + Chemotherapy in First-Line ES-SCLC
2024-511412-25-00Phase 2Authorised
- Sponsor
- Fundación GECP
- Start
- Mar 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, lenvatinib, carboplatin and etoposide in small cell lung cancer (SCLC), sponsored by Fundación GECP. Primary endpoints: Safety and tolerability (Part 1) and Progression-free survival (Part 2). Planned start Mar 2024; status: authorised.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-511412-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511412-25-00.